Acapatamab

艾卡帕妥单抗

Report date: 2026/03/19 16:52:44

Base Information

Drug NameAcapatamab

Drug Alias NameAMG-160

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersProstate-Specific Membrane Antigen inhibitors

TargetsT cell surface glycoprotein CD3Prostate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[15]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeigene Llc

Inactive CompaniesAmgen Inc

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A